The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| STVN | +14.38% | N/A | N/A | +15% |
| S&P | +11% | +85.61% | +13.15% | +53% |
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.
No news articles found for Stevanato Group S.p.A..
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $354.27M | 16.1% |
| Gross Profit | $99.63M | 27.5% |
| Gross Margin | 28.12% | 2.5% |
| Market Cap | $7.03B | 28.9% |
| Net Income | $42.14M | 27.8% |
| EBITDA | $83.88M | 31.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $133.17M | 53.0% |
| Accounts Receivable | $528.19M | 9.0% |
| Inventory | 322.8 | 0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $431.68M | 34.0% |
| Short Term Debt | $97.45M | 19.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.85% | 0.3% |
| Return On Invested Capital | 11.03% | 0.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.52M | 105.0% |
| Operating Free Cash Flow | $60.14M | 171.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 46.57 | 41.39 | 45.63 | 45.26 | 4.62% |
| Price to Book | 4.03 | 3.83 | 4.58 | 4.28 | 11.44% |
| Price to Sales | 4.98 | 4.62 | 5.35 | 5.43 | 17.96% |
| Price to Tangible Book Value | 4.30 | 4.07 | 4.87 | 4.56 | 11.17% |
| Enterprise Value to EBITDA | 72.70 | 103.59 | 100.12 | 88.53 | -1.99% |
| Return on Equity | 9.4% | 9.1% | 9.6% | 9.8% | 4.13% |
| Total Debt | $444.20M | $424.90M | $487.09M | $529.13M | 31.04% |
No podcast episodes available.
STVN earnings call for the period ending June 30, 2022.
STVN earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
